DK1157696T3 - Behandling af rumen-acidose med alpha-amylaseinhibitorer - Google Patents

Behandling af rumen-acidose med alpha-amylaseinhibitorer

Info

Publication number
DK1157696T3
DK1157696T3 DK01304379T DK01304379T DK1157696T3 DK 1157696 T3 DK1157696 T3 DK 1157696T3 DK 01304379 T DK01304379 T DK 01304379T DK 01304379 T DK01304379 T DK 01304379T DK 1157696 T3 DK1157696 T3 DK 1157696T3
Authority
DK
Denmark
Prior art keywords
alpha
treatment
amylase inhibitors
acidosis
rumenic
Prior art date
Application number
DK01304379T
Other languages
Danish (da)
English (en)
Inventor
Bernard Joseph Banks
Mark Andrew Haxell
Graham Lunn
Michael Stephen Pacey
Lee Richard Roberts
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0012760A external-priority patent/GB0012760D0/en
Priority claimed from GB0012793A external-priority patent/GB0012793D0/en
Priority claimed from GB0017495A external-priority patent/GB0017495D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1157696T3 publication Critical patent/DK1157696T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Sustainable Development (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Saccharide Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01304379T 2000-05-24 2001-05-17 Behandling af rumen-acidose med alpha-amylaseinhibitorer DK1157696T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0012760A GB0012760D0 (en) 2000-05-24 2000-05-24 Treatment
GB0012793A GB0012793D0 (en) 2000-05-24 2000-05-24 Treatment
GB0017495A GB0017495D0 (en) 2000-07-17 2000-07-17 Treatment

Publications (1)

Publication Number Publication Date
DK1157696T3 true DK1157696T3 (da) 2007-02-12

Family

ID=27255738

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01304379T DK1157696T3 (da) 2000-05-24 2001-05-17 Behandling af rumen-acidose med alpha-amylaseinhibitorer

Country Status (17)

Country Link
US (1) US20050233983A1 (el)
EP (2) EP1157696B1 (el)
JP (2) JP3798261B2 (el)
KR (1) KR100643946B1 (el)
AT (1) ATE343391T1 (el)
AU (1) AU785303B2 (el)
CA (1) CA2348245C (el)
CY (1) CY1105796T1 (el)
DE (1) DE60124030T2 (el)
DK (1) DK1157696T3 (el)
ES (1) ES2272418T3 (el)
HU (1) HUP0102159A3 (el)
IL (2) IL143225A (el)
MY (1) MY136145A (el)
NZ (1) NZ511877A (el)
PT (1) PT1157696E (el)
TW (1) TWI298021B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1157696T3 (da) * 2000-05-24 2007-02-12 Pfizer Behandling af rumen-acidose med alpha-amylaseinhibitorer
US7906128B2 (en) * 2002-10-21 2011-03-15 Wyeth Llc Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
US7108869B2 (en) * 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
CN1296050C (zh) * 2003-12-10 2007-01-24 浙江海正药业股份有限公司 阿卡波糖肠溶片及制备方法
CN101235061B (zh) * 2007-09-11 2011-03-30 南开大学 一类新的α-淀粉酶抑制剂阿卡他定系列化合物及其应用
WO2010037179A1 (en) 2008-10-03 2010-04-08 Glycan Biosciences Pty Ltd Anionic conjugates of glycosylated bacterial metabolite
DE102009015558B4 (de) * 2009-03-30 2017-04-27 Ulf-Michael Stumpe Bollus zum Eingeben in die Vormägen von Wiederkäuern zur Verbesserung der Vormagenaktivität und Vormagengesundheit
WO2011053578A1 (en) * 2009-10-26 2011-05-05 Pharmachem Laboratories, Inc. Method for treating acidosis in ruminants
CN102212089A (zh) * 2011-04-12 2011-10-12 天津医科大学 一类新的α-淀粉酶抑制剂阿卡他定家族新化合物及其应用
EP3375453A1 (de) * 2017-03-13 2018-09-19 Basf Se Verwendung einer pansengeschützen alpha-amylase
US20220061356A1 (en) * 2018-12-14 2022-03-03 ProAgni Pty Ltd Animal feed composition
CN110899293A (zh) * 2019-10-15 2020-03-24 上海交通大学 一种对阿卡波糖废渣减量化处理的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062950A (en) * 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4175123A (en) * 1976-12-23 1979-11-20 Bayer Aktiengesellschaft Amino-sugar derivatives, process for their preparation and pharmaceutical composition thereof
DE2658562A1 (de) * 1976-12-23 1978-10-12 Bayer Ag Aminozuckerderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
CA1121290A (en) * 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
EP0173950A3 (de) * 1984-09-04 1987-10-28 Hoechst Aktiengesellschaft Neuer alpha-Glukosidase Inhibitor, Verfahren zur seiner Herstellung, seine Verwendung und pharmazeutische Präparate
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US4885361A (en) * 1987-07-31 1989-12-05 Hoffmann-La Roche Inc. Sulfated oligosaccharides
US5021427A (en) * 1988-12-23 1991-06-04 The Board Of Regents, The University Of Texas System Novel pyrrolizidine alkaloid
WO1999026606A2 (en) * 1997-11-25 1999-06-03 Bayer Aktiengesellschaft SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS
DK1157696T3 (da) * 2000-05-24 2007-02-12 Pfizer Behandling af rumen-acidose med alpha-amylaseinhibitorer
US7022684B2 (en) * 2000-05-24 2006-04-04 Pfizer Inc. Treatment of rumen acidosis with α-amylase inhibitors

Also Published As

Publication number Publication date
ATE343391T1 (de) 2006-11-15
CY1105796T1 (el) 2011-02-02
AU785303B2 (en) 2007-01-04
PT1157696E (pt) 2007-01-31
EP1157696A2 (en) 2001-11-28
EP1157696B1 (en) 2006-10-25
JP2005336192A (ja) 2005-12-08
HUP0102159A2 (hu) 2002-01-28
JP3798261B2 (ja) 2006-07-19
HUP0102159A3 (en) 2004-01-28
TWI298021B (en) 2008-06-21
NZ511877A (en) 2002-11-26
EP1157696A3 (en) 2002-02-13
KR100643946B1 (ko) 2006-11-10
EP1745790A2 (en) 2007-01-24
IL143225A (en) 2008-03-20
ES2272418T3 (es) 2007-05-01
HU0102159D0 (en) 2001-08-28
DE60124030D1 (de) 2006-12-07
CA2348245A1 (en) 2001-11-24
CA2348245C (en) 2007-12-11
MY136145A (en) 2008-08-29
DE60124030T2 (de) 2007-04-12
IL143225A0 (en) 2002-04-21
US20050233983A1 (en) 2005-10-20
JP2002047209A (ja) 2002-02-12
EP1745790A3 (en) 2007-03-21
KR20010107661A (ko) 2001-12-07
IL186223A0 (en) 2008-01-20
AU4619201A (en) 2001-11-29

Similar Documents

Publication Publication Date Title
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
AU2003291227A8 (en) Antibacterial agents
TR200103216T2 (tr) Pirimidinon bileşimleri
GB0031088D0 (en) Medicaments
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
EA200300375A1 (ru) Производные 2-амино-2-алкил-4-гексеновой и -гексиновой кислот, которые могут быть использованы в качестве ингибиторов синтетазы оксида азота
MY138285A (en) Fab i inhibitors
TR200002759T2 (tr) Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı.
TR200100805T2 (tr) Tetrahidropiridoeterler
DK1157696T3 (da) Behandling af rumen-acidose med alpha-amylaseinhibitorer
ATE461928T1 (de) Antibakterielle wirkstoffe
DE60042401D1 (de) Fab-i inhibitoren
EE05056B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
DK1841765T5 (da) Imidazo[4,5-C]pyridinforbindelse og fremgangsmåde til antiviral behandling
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
DK1015437T3 (da) Benzoxazin- og benzothiazin-derivater og deres anvendelse i lægemidler
DK1240313T3 (da) Enzymer, som er homologe med heparanase og splejsningsvarianter deraf
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
WO2001008668A3 (en) Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
DK1239861T3 (da) Kombinationaf cyamemazin og et atypisk neuroleptikum
IS6618A (is) Hýgrómýsín A afleiður til meðhöndlunar á bakteríu- og frumdýrasýkingum
DE60014915D1 (de) Hypoxanthin- und thiohypxanthin-verbindungen
DK0974353T3 (da) Anvendelse af homocysteinderivater til behandling af bakterielle infektioner